Because resistance to beta-lactam and macrolide antibiotics is increasing, seriously ill patients may be treated with an advanced-generation cephalosporin (eg, ceftriaxone or cefotaxime) based on minimal inhibitory concentration (MIC); other options include a respiratory fluoroquinolone (eg, moxifloxacin, levofloxacin), a tetracycline (eg, omadacycline), or a pleuromutilin (eg, lefamulin).